SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

L-701,324

Item No. 30687

CAS Registry No.:	142326-59-8
Formal Name:	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone
MF:	$C_{21}H_{14}ClNO_3$
FW:	363.8
Purity:	≥98%
UV/Vis.:	λ_{max}: 226 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

L-701,324 is supplied as a crystalline solid. A stock solution may be made by dissolving the L-701,324 in the solvent of choice, which should be purged with an inert gas. L-701,324 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of L-701,324 in these solvents is approximately 15 and 30 mg/ml, respectively.

L-701,324 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, L-701,324 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. L-701,324 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

L-701,324 is an NMDA receptor antagonist.[1] It inhibits NMDA-induced currents in rat cortical neurons (K_i = 5.4 nM). L-701,324 inhibits seizures induced by N-methyl-DL-aspartate, pentylenetetrazole (PTZ; Item No. 18682), or electroshock, as well as audiogenic seizures in mice (ED_{50}s = 3.5, 2.8, 1.4, and 0.96 mg/kg, respectively).[2] It reduces the number of audiogenic seizures in a rat model of ethanol-induced withdrawal seizures when administered at a dose of 5 mg/kg.[3] L-701,324 (2.5 and 5 mg/kg) reduces amphetamine-induced hyperactivity in rats.[4]

References

1. Priestley, T., Laughton, P., Macaulay, A.J., *et al.* Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324. *Neuropharmacology* **35(11)**, 1573-1581 (1996).
2. Bristow, L.J., Hutson, P.H., Kulagowski, J.J., *et al.* Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. *J. Pharmacol. Exp. Ther.* **279(2)**, 492-501 (1996).
3. Kotlinska, J. and Liljequist, S. Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. *Psychopharmacology (Berl)* **127(3)**, 238-244 (1996).
4. Bristow, L.J., Flatman, K.L., Hutson, P.H., *et al.* The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents. *J. Pharmacol. Exp. Ther.* **277(2)**, 578-585 (1996).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM